

# PROGRAMA ACADÉMICO

**BEST OF ASCO®**  
OFFICIALLY LICENSED

**CIUDAD DE MEXICO**

del 26 al 28 de julio, 2023



#cancerinmamila  
#cancerderinon  
#melanoma  
#hepatocarcinoma  
#cancerdemama  
#cancerdecabezaycuello  
#cancerdepulmon  
#cancerdepulmondecélulas  
#cancerdepancreas

medicine.matters@medicalrp.com.mx  
999 5497809

Inscripciones abiertas:  
congresosmpr.com.mx

Powered by  
**MPR**  
MEDICAL PHARMA RESEARCH LATAM  
LÍDERES EN PROGRAMAS DE EDUCACIÓN  
MÉDICA CONTINUA EN AMÉRICA LATINA

Estamos celebrando el 11<sup>vo</sup> aniversario del exitoso programa de educación médica continua **Best of ASCO® CDMX 2023, Licencia Oficial**, donde se presentarán los últimos avances en **Oncología, Oncología Clínica, Radio Oncología, Cirugía Oncológica**. El cual se llevará a cabo de **forma 100% Online**.



## Miércoles 26 de Julio

### 8:45 Inauguración

INAUGURACIÓN: Dr. Aglés Cruz Avelar (UNAM), Dr. Jorge Martínez Cedillo (CMO), Dr. Rafael Medrano Guzman (IMSS), Dra. Guadalupe Cervantes Sánchez (ISSSTE).

Dr. Tomás Daniel  
Sánchez Cárdenas:  
Maestro de Ceremonias

## CANCER DE MAMA LOCAL

9:00 501. Efficacy and safety results by age in monarche: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC).

Dra. Georgina Garnica  
Jaliffe

9:15 517. Effects of ovarian ablation or suppression on breast cancer recurrence and survival: Patient-level meta-analysis of 14,993 pre-menopausal women in 25 randomized trials.

Dr. Alberto Suárez Zaizar

9:30 Desde mi punto de Vista...

Dra. Marlen Nava Tapia

9:45 Mesa Redonda

Dra. Guadalupe Cervantes  
Sánchez, CMN 20 de Nov.

10:05 CDK4/6 inhibitors in early breast cancer treatment (NATALEE study)

Dr. Stephen Chia, U.  
British Columbia

10:50 **COFFEE BREAK**

## GINECOLÓGICOS

11:20 5503. Dostarlimab for primary advanced or recurrent (A/R) endometrial cancer (EC): Outcomes by blinded independent central review (BICR) of the RUBY trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).

Dra. Rocío Baltazar  
Contreras

11:35 5509. Final survival analysis of the phase III OVHIPEC-1 trial of hyperthermic intraperitoneal chemotherapy in ovarian cancer after ten year follow-up.

Dr. Ramón Hernández  
García

11:50 Mesa redonda

Dr. Mario Escobar Gómez,  
Hosp. Gral. SS

## Miércoles 26 de Julio

### SNC

- |       |  |  |
|-------|--|--|
| 12:10 | LBA1. INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation. | Dra. Mayra Galeana Hernández                 |
| 12:25 | 2009 Clinical and analytical validation of a targeted gene expression biomarker predicting meningioma outcomes and radiotherapy responses.                                     | Dr. Ulises Mejía Gamboa                      |
| 12:40 | Mesa Redonda   | Dr. Víctor Rodríguez González, Hosp. Militar |

### MISCELÁNEOS

- |       |  |                                     |
|-------|--|-------------------------------------|
| 13:00 | 12000. A multicenter randomized controlled trial (RCT) for the effectiveness of Comprehensive Geriatric Assessment (CGA) with extensive patient coaching on quality of life (QoL) in older patients with solid tumors receiving systemic therapy: G-oncoCOACH study. | Dr. Enrique Soto Pérez              |
| 13:15 | 12006 Reduced symptom burden after implementation of an electronic symptom management program.   | Dra. Andrea Castro Sánchez          |
| 13:30 | 2510. First-line treatment of fecal microbiota transplantation for immune-mediated colitis.  | Dr. Francisco Vera Badillo          |
| 13:45 | Mesa Redonda   | Dr. Saúl Campos Gómez, COE. ISSEMYM |
| 14:05 | <b>CIERRE DEL DÍA</b>  |                                     |

## Jueves 27 de Julio

### PULMÓN

- |       |   |                                   |
|-------|---|-----------------------------------|
| 09:00 | LBA100 KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.                      | Dr. Rodrigo Riera Salas           |
| 09:10 | LBA3. OS survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mut stage 1B-IIIa NSCLC   | Dr. Fabian Martínez Herrera       |
| 09:20 | LBA8505 Oral Abstract Session IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (Pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial. | Dr. Manuel Martínez Barrera       |
| 09:30 | LBA9000. Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.                                     | Dr. Jerónimo Rodríguez Cid        |
| 09:40 | Mesa Redonda  | Dr. Jorge Alatorre Alexander INER |
| 10:00 | 5066. Enzalutamide vs abiraterone in patients with prostate cancer with and without type 2 diabetes mellitus. Cómo seleccionar la mejor opción terapéutica en cáncer de próstata en pacientes con comorbilidades        | Dra. Perla Pérez Pérez            |
| 10:45 | COFFEE BREAK  |                                   |

### GENITO URINARIO

- |       |  |                              |
|-------|--|------------------------------|
| 11:05 | LBA4500 Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study. | Dra. Andrea Remolina Bonilla |
|-------|--|------------------------------|



## Jueves 27 de Julio

- |       |  |                                     |
|-------|--|-------------------------------------|
| 11:20 | LBA4507 Multicenter randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle-invasive bladder cancer (MIBC): Overall survival (OS) data at 5 years in the GETUG/AFU V05 VESPER trial. | Dr. Héctor de la Mora Molina        |
| 11:35 | LBA5000. Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design.   | Dra. Haydeé Verduzco Aguirre        |
| 11:50 | Mesa Redonda   | Dr. Álvaro Aguayo González, INCMNSZ |

### CABEZA Y CUELLO

- |       |  |  |
|-------|--|--|
| 12:10 | 6007. Neoadjuvant nivolumab, paclitaxel, and carboplatin followed by response-stratified chemoradiation in locoregionally advanced HPV negative head and neck squamous cell carcinoma (HNSCC): The DEPEND trial.   | Dra. Marlid Cruz Ramos.                    |
| 12:25 | 6003. Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab combined with weekly paclitaxel carboplatin in first-line in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible for cisplatin-based therapies. | Dr. Marcos López Naveda                    |
| 12:40 | Mesa Redonda   | Dr. Adalberto Toriz Hernández, Hosp. Naval |

## Jueves 27 de Julio

### CIRUGÍA

- |       |  |  |
|-------|--|--|
| 13:00 | 3520 Sustained organ preservation in rectal cancer patients treated with total neoadjuvant therapy: Long-term results of the OPRA trial.   | Dra. Itzel Vela Sarmiento                    |
| 13:15 | LBA5511 An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC). A Gynecologic Cancer Intergroup study led by the Canadian Cancer Trials Group (CCTG CX.5-SHAPE). | Dr. Emilio Olaya Guzmán                      |
| 13:30 | Mesa Redonda   | Dr. Pabel Miranda Aguirre,<br>CMN 20 de Nov. |
| 13:50 | <b>CIERRE DEL DÍA</b>  |  |

## Viernes 28 de Julio

8:00 Desayuno con el Experto

### GASTRO INTESTINAL

- 09:00 LBA2 PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048). Dr. Karim Dip Borunda
- 09:15 3508 Efficacy of panitumumab in patients with left-sided disease, MSS/MSI-L, and RAS/BRAF WT: A biomarker study of the phase III PARADIGM trial. Dra. Consuelo Diaz Romero
- 09:30 4008. Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2-amplified biliary tract cancer (BTC). Dra. Lizbeth Enriquez Román
- 09:45 4006 Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12- and 18-month survival rates from the phase 3 NAPOLI 3 trial. Dra. Haide Nuñez López
- 10:00 Mesa Redonda Dr. Rafael Medrano Guzmán, CMN Siglo XXI
- 10:20 COFFEE BREAK

### MELANOMA

- 10:50 101. The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: Three-year data of PRADO and OpACIN-neo. Dr. Jorge Ramos Olivares
- 11:05 LBA9503. Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial. Dr. Alberto Sánchez Prieto

## Viernes 28 de Julio

11:20	LBA9505 Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study.	Dr. Sergio Buenaventura Cisneros
11:35	Mesa Redonda	Dr. Sergio Buenaventura Cisneros, Clínica 25 Mty, NL
11:55	Opciones Terapéuticas en Von Hippel Lindau	Dr. Alejandro Sánchez , Univ. de Utah, USA

## MAMA METASTÁSICO

12:40	Desde mi Punto de Vista...	Dra. Brenda Carbajal S. CITI Cáncer Oaxaca
13:00	1003 Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2–negative (HR+/HER2–) metastatic breast cancer (mBC).	Dra. Rocio Grajales Álvarez
13:15	1007 Randomized trial of fixed dose capecitabine compared to standard dose capecitabine in metastatic breast cancer: The X-7/7 trial.	Dra. Luz Valenzuela López
13:30	LBA1000 Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2–negative (HER2–) advanced breast cancer (ABC).	Dra. Rocío Grajales Álvarez
13:45	1006 An age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2–positive (HER2+) metastatic breast cancer (mBC) from DESTINY–Breast01, –02, and –03.	Dr. Carlos González Núñez
14:00	Mesa Redonda	Dra. Paula Cabrera Galeana , INCAN
14:20	<b>CIERRE DEL DÍA</b>	



## Comité Científico

**Dra. Guadalupe  
Cervantes Sánchez**



**Presidenta del Comité  
Científico Best OF ASCO CDMX**

**Dr. Pabel  
Miranda Aguirre.**



**VP del Comité  
Científico Best OF ASCO CDMX**

## Coordinadores de módulo

### COORDINADOR

### MÓDULO

Dra. Guadalupe Cervantes	CMN 20 de Nov.	Cáncer de Mama Local
Dr. Mario Escobar Gómez	Hosp. Gral. SS	Tumores Ginecológicos
Dr. Víctor Rodríguez González	Hosp. Militar	Sistema Nervioso Central
Dr. Saúl Campos Gómez	COE. ISSEMYM	Misceláneos
Dr. Jorge Alatorre Alexander	INER	Cáncer de Pulmón
Dr. Pabel Miranda Aguirre	CMN 20 de Nov.	Cirugía Oncológica
Dr. Rafael Medrano Guzmán	CMN Siglo XXI	Gastro Intestinal
Dr. Sergio Buenaventura	Clínica 25 Mty NL	Melanoma
Dra. Paula Cabrera	INCAN	Cáncer de Mama
Dr. Adalberto Toriz Hernández	Hosp. Naval	Cabeza y Cuello

# FACULTATIVOS

Dra. Baltazar Contreras Rocio  
Dr. Buenaventura Cisneros Sergio  
Dra. Carbajal Saldaña Brenda  
Dra. Castro Sánchez Andrea  
Dr. Chia Stephen. U. British Columbia  
Dra. Cruz Ramos Marlid  
Dr. De la Mora Molina Héctor  
Dra. Díaz Romero Consuelo  
Dr. Dip Borunda Karim  
Dra. Enriquez Román Lizbeth  
Dra. Galeana Hernández Mayra  
Dra. Garnica Jaliffe Georgina  
Dr. González Nuñez Carlos  
Dra. Grajales Álvarez Rocío  
Dr. Hernández García Ramón  
Dr. López Naveda Marcos  
Dr. Martínez Barrera Luis Manuel  
Dr. Martínez Herrera Fabián  
Dr. Mejía Gamboa Ulises

Dra. Nava Tapia Marlen  
Dra. Nuñez López Haide Nayeli  
Dr. Olaya Guzmán Emilio  
Dra. Pérez Pérez Perla  
Dr. Ramos Olivares Jorge Alberto  
Dra. Remolina Bonilla Andrea Yuli  
Dr. Riera Salas Rodrigo  
Dr. Rodríguez Cid Jerónimo  
Dr. Sánchez Alejandro, Univ. de Utah,  
USA  
Dr. Sánchez Prieto Mario Alberto  
Dr. Soto Pérez de Celis Enrique  
Dr. Suárez Zaizar Alberto  
Dra. Valenzuela López Luz Teresa  
Dra. Vela Sarmiento Itzel  
Dr. Vera Badillo Francisco, Kingston  
HSC, Ontario, Ca.  
Dra. Verduso Aguirre Haydeé Cristina

Powered by:



**MPR**

MEDICAL PHARMA RESEARCH LATAM  
LIBRES EN PROGRAMAS DE EDUCACIÓN  
MÉDICA CONTINUA EN AMÉRICA LATINA